Gur Roshwalb currently serves as Chief Executive Officer at 1E Therapeutics since July 2024 and holds the position of Board Observer at CPTx as of August 2024. Previously, Gur Roshwalb was a Board Member at KAHR-Medical Ltd., Biosplice Therapeutics, AltruBio Inc., and MiNA Therapeutics, and served as a Board Member at Viracta Therapeutics, Inc. from December 2020 to June 2022. Gur Roshwalb was also CEO at Zywie Bio LLC from October 2017 to December 2018 and provided strategic and financial consulting at GeNO, LLC in 2017. Academic credentials include an MBA in Finance from NYU Stern School of Business, an MD from Albert Einstein College of Medicine, and a BA in East Asian Languages and Culture/Mathematics from Columbia University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices